Trusted Resources: Evidence & Education
Scientific literature and patient education texts
How I Treat Acute and Persistent Sickle Cell Pain
source: Mediterranean Journal of Hematology and Infectious Diseases
year: 2020
authors: Samir K. Ballas
summary/abstract:Sickle pain is the hallmark of sickle cell disease (SCD). It could be acute, persistent/relapsing, chronic, or neuropathic. Although there is a general consensus that pain is a major manifestation of SCD, there is a controversy as to the types of pain and their interrelationship between acute, chronic, relapsing, persistent, etc. This report first reviews the general approach to the management of acute vaso-occlusive crisis (VOC) pain, including education, counseling, pharmacotherapy, non-pharmacotherapy, and fluid therapy. This is followed by the presentation of five patients that represent typical issues that are commonly encountered in the management of patients with SCD.
These issues are: individualized treatment of pain, bilaterality of pain, use of illicit drugs, tolerance to opioids, opioid-induced hyperalgesia, and withdrawal syndrome. The clinical aspects and management of each of these issues are described. Moreover, such complications as tolerance and withdrawal may persist after discharge and may be mistaken as chronic pain rather than resolving, persistent or relapsing pain.
organization: Thomas Jefferson University, USADOI: 10.4084/mjhid.2020.064
read more
Related Content
-
Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized tr...Clinical and preclinical data demonstrat...
-
Blood Transfusions: What You Need to Know and Do (Part 2: Blood Matching)https://www.youtube.com/watch?v=bs4bRApy...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
Pain and opioid use after reversal of sickle cell disease following hematopoietic stem cell transplantPain is the most common symptom of sickl...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
In A 1st, Doctors In U.S. Use CRISPR Tool To Treat Patient With Genetic DisorderFor the first time, doctors in the U.S. ...
-
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disea...Ironwood Pharmaceuticals, Inc., a commer...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.